rXsight director Corley Jesse Anderson acquires $100,004 in shares

RxSight, based mostly in Aliso Viejo, California, focuses on ophthalmic items and continues to be an lively participant within the medical expertise sector. The corporate maintains a strong stability sheet with more money than debt, positioning it effectively for future progress alternatives. The corporate maintains a strong stability sheet with more money than debt, positioning it effectively for future progress alternatives.

RxSight, based mostly in Aliso Viejo, California, focuses on ophthalmic items and continues to be an lively participant within the medical expertise sector. The corporate maintains a strong stability sheet with more money than debt, positioning it effectively for future progress alternatives.

RxSight, based mostly in Aliso Viejo, California, focuses on ophthalmic items and continues to be an lively participant within the medical expertise sector.

In different latest information, RxSight Inc. has been the topic of a number of latest analyst changes. Stifel has downgraded their score on the corporate’s shares and diminished their worth goal as a consequence of considerations about competitors and worldwide enlargement efforts. The agency’s resolution adopted a overview of RxSight’s This fall 2024 preliminary outcomes, which reported a complete income of $40.2 million, aligning with each Stifel’s and consensus estimates.

In distinction, Needham & Firm maintained a optimistic stance on RxSight, reiterating a Purchase score. The corporate’s income forecast for 2025 surpassed consensus estimates, projecting revenues to be between $185 million and $197 million. Nonetheless, Stifel and Wells Fargo (NYSE:WFC) downgraded RxSight’s inventory as a consequence of slowing adoption projections and restricted progress potential respectively.

UBS initiated protection on RxSight with a Purchase score, highlighting the corporate’s robust place within the U.S. cataract surgical procedure market and projecting over 20% gross sales progress via 2028. These latest developments replicate a various vary of views from analysts concerning the way forward for RxSight.

This text was generated with the assist of AI and reviewed by an editor. For extra info see our T&C.